Oral subchronic toxicity study and genetic toxicity evaluation of mitoquinone mesylate

Mitochondrial dysfunction and excessive reactive oxygen species production contributes to the pathophysiology of aging. Coenzyme Q10 is thought to protect mitochondria from oxidative damage; thus, mitoquinone was developed as mitochondria‐targeted analogue with similar antioxidant activity. Mitoquin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of applied toxicology 2024-10, Vol.44 (10), p.1555-1571
Hauptverfasser: Mitchell, E. Siobhan, Lemke, Shawna, Woodhead, Brendon, Coleman, David
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Mitochondrial dysfunction and excessive reactive oxygen species production contributes to the pathophysiology of aging. Coenzyme Q10 is thought to protect mitochondria from oxidative damage; thus, mitoquinone was developed as mitochondria‐targeted analogue with similar antioxidant activity. Mitoquinone is the oxidized form of mitoquinol. Mitoquinone/mitoquinol mesylate has been proposed as a food ingredient. As part of the safety analysis, we performed genotoxicity assays and a 39‐week toxicity study to determine overall toxicity potential. Mitoquinone mesylate showed no evidence of genotoxic potential in two in vitro assays, bacterial reverse mutation and human lymphocyte chromosome aberration, nor in the in vivo micronucleus test in rats. In the 39‐week study in dogs, there were no findings observed, which were considered to represent adverse systemic toxicity; therefore, the high dose level (40 mg/kg/day) was considered the NOAEL. The principal findings in this study were fecal disturbances and vomiting. These findings were considered to be due to a local, possibly irritant effect of the test substance on the gastrointestinal tract and were not considered adverse as there were no impacts on clinical or histopathology. This highest dose exceeds the expected daily human intake more than 100‐fold. Data from well‐designed clinical trials actively collecting safety endpoints corroborate that 20 mg/day can be safely consumed and is not likely to result in significant gastrointestinal complaints. These results support the conclusion that the use of mitoquinone/mitoquinol mesylate as a food ingredient is safe. Mitochondrial dysfunction and excessive reactive oxygen species production contributes to the pathophysiology of aging. Mitoquinone/mitoquinol was developed as mitochondria‐targeted analogue to Coenzyme Q10 with similar antioxidant activity but is not a substrate for oxidative phosphorylation. Studies show it is not genotoxic and had a NOAEL of 40 mg/kg/day in a 39‐week study. This dose exceeds the expected daily human intake more than 100‐fold. These results support the conclusion that the use of mitoquinone/mitoquinol mesylate as a food ingredient is safe.
ISSN:0260-437X
1099-1263
1099-1263
DOI:10.1002/jat.4654